PD-1/PD-L and autoimmunity: A growing relationship

Cellular Immunology

Volumn 310, Issue , 2016, Pages 27-41

  Zamani, Mohammad Reza ^a,b   Aslani, Saeed ^a   Salmaninejad, Arash ^b,c   Javan, Mohammad Reza ^d   Rezaei, Nima ^a,b,e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSAL SCIENTIFIC EDUCATION AND RESEARCH NETWORK USERN   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmunity; PD 1; PD L1; PD L2

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; SEX HORMONE;

ALLERGIC ENCEPHALOMYELITIS; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE UVEITIS; AUTOIMMUNITY; BEHCET DISEASE; GENE; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MYASTHENIA GRAVIS; MYOCARDITIS; NONHUMAN; PDCD1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, CD274; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GONADAL STEROID HORMONES; HUMANS; IMMUNE TOLERANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84997283981     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2016.09.009     Document Type: Review

References (191)

1. [1] Tobón, G.J., et al. Are autoimmune diseases predictable?. Autoimmun. Rev. 11:4 (2012), 259–266.
2. [2] Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13:4 (2013), 227–242.
3. [3] Nurieva, R.I., Liu, X., Dong, C., Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol. Rev. 229:1 (2009), 88–100.
4. [4] Saresella, M., et al. The PD-1/PD-L1 pathway in human pathology. Curr. Mol. Med. 12:3 (2012), 259–267.
5. [5] Chemnitz, J.M., et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:2 (2004), 945–954.
6. [6] Yokosuka, T., et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209:6 (2012), 1201–1217.
7. [7] Nishimura, H., Honjo, T., Minato, N., Facilitation of β selection and modification of positive selection in the thymus of PD-1–deficient mice. J. Exp. Med. 191:5 (2000), 891–898.
8. [8] Hebeisen, M., et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123:3 (2013), 1044–1056.
9. [9] Keir, M.E., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203:4 (2006), 883–895.
10. [10] Latchman, Y., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:3 (2001), 261–268.
11. [11] Latchman, Y.E., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. U.S.A. 101:29 (2004), 10691–10696.
12. [12] Dong, H., et al. B7–H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:12 (1999), 1365–1369.
13. [13] Tseng, S.-Y., et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:7 (2001), 839–846.
14. [14] Nishimura, H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:2 (1999), 141–151.
15. [15] Liang, S.C., et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:10 (2003), 2706–2716.
16. [16] Brown, J.A., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:3 (2003), 1257–1266.
17. [17] Nishimura, H., et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4–CD8–) thymocytes. Int. Immunol. 8:5 (1996), 773–780.
18. [18] Keir, M.E., Freeman, G.J., Sharpe, A.H., PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J. Immunol. 179:8 (2007), 5064–5070.
19. [19] Blank, C., et al. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 171:9 (2003), 4574–4581.
20. [20] Zucchelli, S., et al. Defective central tolerance induction in NOD mice: genomics and genetics. Immunity 22:3 (2005), 385–396.
21. [21] Rodig, N., et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33:11 (2003), 3117–3126.
22. [22] Probst, H.C., et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6:3 (2005), 280–286.
23. [23] Sharpe, A.H., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8:3 (2007), 239–245.
24. [24] Watson, M.P., George, A.J., Larkin, D.F., Differential effects of costimulatory pathway modulation on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 47:8 (2006), 3417–3422.
25. [25] Francisco, L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206:13 (2009), 3015–3029.
26. [26] Munoz, M.G., Witkin, S.S., Activation of circulating γδ T-lymphocytes by autologous sperm from men sensitized to sperm. J. Reprod. Immunol. 25:3 (1993), 265–275.
27. [27] Dal Secco, V., et al. Mouse Sertoli cells display phenotypical and functional traits of antigen-presenting cells in response to interferon gamma. Biol. Reprod. 78:2 (2008), 234–242.
28. [28] Guleria, I., et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202:2 (2005), 231–237.
29. [29] D'Addio, F., et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 187:9 (2011), 4530–4541.
30. [30] Mallampalli, M.P., et al. Role of environment and sex differences in the development of autoimmune diseases: a roundtable meeting report. J. Womens Health 22:7 (2013), 578–586.
31. [31] Holroyd, C., Edwards, C., The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus. Climacteric 12:5 (2009), 378–386.
32. [32] Yildirim-Toruner, C., Diamond, B., Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol. 127:2 (2011), 303–312.
33. [33] Selmi, C., Invernizzi, P., Gershwin, M.E., The X chromosome and systemic sclerosis. Curr. Opin. Rheumatol. 18:6 (2006), 601–605.
34. [34] Nie, J., et al. FOXP3+ Treg cells and gender bias in autoimmune diseases. Front. Immunol., 6, 2015.
35. [35] Bodhankar, S., Offner, H., PD-1 interaction with PD-L1 but not PD-L2 on B cells mediates protective effects of estrogen against EAE (P5176). J. Immunol., 2013, 1945, 190.5 (Meeting Abstracts 1).
36. [36] Polanczyk, M.J., et al. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int. Immunol. 19:3 (2007), 337–343.
37. [37] Rosenblum, M.D., Way, S.S., Abbas, A.K., Regulatory T cell memory. Nat. Rev. Immunol. 16:2 (2016), 90–101.
38. [38] Francisco, L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206:13 (2009), 3015–3029.
39. [39] Budhu, S., et al. Blockade of surface bound TGF-β on regulatory T cells abrogates suppression of effector T cell function within the tumor microenvironment (TUM2P. 1015). J. Immunol., 194(1 Suppl.), 2015 p. 69.12–69.12.
40. [40] Boussiotis, V.A., Chatterjee, P., Li, L., Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. Cancer J. 20:4 (2014), 265–271.
41. [41] Fontenot, J.D., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22:3 (2005), 329–341.
42. [42] Kim, J.M., Rasmussen, J.P., Rudensky, A.Y., Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:2 (2007), 191–197.
43. [43] Huter, E.N., et al. TGF-β-induced Foxp3+ regulatory T cells rescue scurfy mice. Eur. J. Immunol. 38:7 (2008), 1814–1821.
44. [44] Bennett, C.L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27:1 (2001), 20–21.
45. [45] Wildin, R.S., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27:1 (2001), 18–20.
46. [46] Thomson, A.W., Turnquist, H.R., Raimondi, G., Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:5 (2009), 324–337.
47. [47] Parsa, A.T., et al. Loss of tumor suppressor PTEN function increases B7–H1 expression and immunoresistance in glioma. Nat. Med. 13:1 (2007), 84–88.
48. [48] Atkinson, M.A., The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb. Perspect. Med., 2(11), 2012, a007641.
49. [49] Fife, B.T., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal. Nat. Immunol. 10:11 (2009), 1185–1192.
50. [50] Unger, W.W., et al. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD-L1. Eur. J. Immunol. 39:11 (2009), 3147–3159.
51. [51] Guleria, I., et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin. Immunol. 125:1 (2007), 16–25.
52. [52] Wang, J., et al. Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. U.S.A. 102:33 (2005), 11823–11828.
53. [53] Yadav, D., et al. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. Cell. Immunol. 258:2 (2009), 161–171.
54. [54] Ansari, M.J.I., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:1 (2003), 63–69.
55. [55] Martin-Orozco, N., et al. Cutting edge: programed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J. Immunol. 177:12 (2006), 8291–8295.
56. [56] Kadri, N., et al. CD4+ type II NKT cells mediate ICOS and programmed death-1–dependent regulation of type 1 diabetes. J. Immunol. 188:7 (2012), 3138–3149.
57. [57] Wang, C.-J., et al. Protective Role of Programmed Death 1 Ligand 1 (PD-L1) in Nonobese Diabetic Mice The Paradox in Transgenic Models. Diabetes 57:7 (2008), 1861–1869.
58. [58] Subudhi, S.K., et al. Local expression of B7–H1 promotes organ-specific autoimmunity and transplant rejection. J. Clin. Investig. 113:5 (2004), 694–700.
59. [59] Owens, T., Sriram, S., The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol. Clin. 13:1 (1995), 51–73.
60. [60] Viglietta, V., et al. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:7 (2004), 971–979.
61. [61] Chen, L., et al. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocular Immunol. Inflammation 17:1 (2009), 47–55.
62. [62] Salama, A.D., et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198:1 (2003), 71–78.
63. [63] Carter, L.L., et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182:1 (2007), 124–134.
64. [64] Liu, Y., et al. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 12:5 (2006), 518–525.
65. [65] Wang, C., et al. Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J. Neurosci. Res. 88:1 (2010), 7–15.
66. [66] Hemmer, B., et al. Pathogenesis of multiple sclerosis: an update on immunology. Curr. Opin. Neurol. 15:3 (2002), 227–231.
67. [67] Kohm, A.P., et al. Cutting edge: CD4+ CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169:9 (2002), 4712–4716.
68. [68] Reddy, J., et al. Myelin proteolipid protein-specific CD4+ CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 101:43 (2004), 15434–15439.
69. [69] Baecher-Allan, C., et al. CD4+ CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Generation and Effector Functions of Regulatory Lymphocytes: Novartis Foundation Symposium 252, 2003, Wiley Online Library.
70. [70] Javan, M.R., et al. Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis. Iran. J. Allergy Asthma Immunol., 2016.
71. [71] Krupnick, A.S., et al. Cutting edge: murine vascular endothelium activates and induces the generation of allogeneic CD4+ 25+ Foxp3+ regulatory T cells. J. Immunol. 175:10 (2005), 6265–6270.
72. [72] Loftus, E.V. Jr, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:6 (2004), 1504–1517.
73. [73] Katz, J.A., Management of inflammatory bowel disease in adults. J. Digest. Dis. 8:2 (2007), 65–71.
74. [74] Reinecker, H.C., et al. Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease. Clin. Exp. Immunol. 94:1 (1993), 174–181.
75. [75] Uhlig, H.H., et al. Characterization of Foxp3+ CD4+ CD25+ and IL-10-secreting CD4+ CD25+ T cells during cure of colitis. J. Immunol. 177:9 (2006), 5852–5860.
76. [76] Nakazawa, A., et al. The expression and function of costimulatory molecules B7H and B7–H1 on colonic epithelial cells. Gastroenterology 126:5 (2004), 1347–1357.
77. [77] Totsuka, T., et al. Regulation of murine chronic colitis by CD4+ CD25–programmed death-1+ T cells. Eur. J. Immunol. 35:6 (2005), 1773–1785.
78. [78] Totsuka, T., et al. Immunosenescent colitogenic CD4+ T cells convert to regulatory cells and suppress colitis. Eur. J. Immunol. 38:5 (2008), 1275–1286.
79. [79] Kiesler, P., Fuss, I.J., Strober, W., Experimental models of inflammatory bowel diseases. CMGH Cell. Mol. Gastroenterol. Hepatol. 1:2 (2015), 154–170.
80. [80] Barber, D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:7077 (2005), 682–687.
81. [81] Day, C.L., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:7109 (2006), 350–354.
82. [82] Kondo, Y., et al. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 57 (2016), 54–60.
83. [83] Müller-Ladner, U., et al. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1:2 (2005), 102–110.
84. [84] McInnes, I.B., O'Dell, J.R., State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69:11 (2010), 1898–1906.
85. [85] de Kleer, I.M., et al. CD4+ CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172:10 (2004), 6435–6443.
86. [86] Keystone, E.C., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50:5 (2004), 1400–1411.
87. [87] Nadkarni, S., Mauri, C., Ehrenstein, M.R., Anti–TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J. Exp. Med. 204:1 (2007), 33–39.
88. [88] Morgan, M.E., et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 48:5 (2003), 1452–1460.
89. [89] Frey, O., et al. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+ CD25+ T cells. Arthritis Res. Ther., 7(2), 2005, R291.
90. [90] Morgan, M.E., et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 52:7 (2005), 2212–2221.
91. [91] Ehrenstein, M.R., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200:3 (2004), 277–285.
92. [92] Cao, D., et al. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 6:4 (2004), R335–R346.
93. [93] Raghavan, S., et al. FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann. Rheum. Dis. 68:12 (2009), 1908–1915.
94. [94] Möttönen, M., et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Immunol. 140:2 (2005), 360–367.
95. [95] Wan, B., et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177:12 (2006), 8844–8850.
96. [96] Hatachi, S., et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30:7 (2003), 1410–1419.
97. [97] Myers, L.K., et al. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61:19 (1997), 1861–1878.
98. [98] Wang, G., et al. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol. Int. 31:4 (2011), 513–519.
99. [99] Song, M.-Y., et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut, 2014 p. gutjnl-2014-307311.
100. [100] Racanelli, V., Rehermann, B., The liver as an immunological organ. Hepatology 43:S1 (2006), S54–S62.
101. [101] Krawitt, E.L., Autoimmune hepatitis. N. Engl. J. Med. 354:1 (2006), 54–66.
102. [102] Manns, M.P., Vogel, A., Autoimmune hepatitis, from mechanisms to therapy. Hepatology 43:S1 (2006), S132–S144.
103. [103] Sakaguchi, S., Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004), 531–562.
104. [104] Kido, M., et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 135:4 (2008), 1333–1343.
105. [105] Oikawa, T., et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol. Int. 57:8 (2007), 485–492.
106. [106] Mühlbauer, M., et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-α and-γ and mediates T cell apoptosis. J. Hepatol. 45:4 (2006), 520–528.
107. [107] Aoki, N., et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology, 140(4), 2011 p. 1322–1333.e5.
108. [108] Ma, L., et al. Tfh and plasma cells are correlated with hypergammaglobulinaemia in patients with autoimmune hepatitis. Liver Int. 34:3 (2014), 405–415.
109. [109] Miyake, Y., et al. Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatol. Res. 44:13 (2014), 1299–1307.
110. [110] Matsumoto, K., et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 29:1 (2014), 110–115.
111. [111] Chen, C.-L., et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology, 2016 (just-accepted).
112. [112] Iwai, Y., et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:1 (2003), 39–50.
113. [113] Mataki, N., et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am. J. Gastroenterol. 102:2 (2007), 302–312.
114. [114] Rehermann, B., Nascimbeni, M., Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:3 (2005), 215–229.
115. [115] Keir, M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704.
116. [116] Urbani, S., et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J. Hepatol. 48:4 (2008), 548–558.
117. [117] Nakamoto, N., et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology, 134(7), 2008 p. 1927–1937.e2.
118. [118] Gardiner, D., et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One, 8(5), 2013, e63818.
119. [119] Dong, H., et al. B7–H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes. Immunity 20:3 (2004), 327–336.
120. [120] Semmo, N., et al. Preferential loss of IL-2–secreting CD4+ T helper cells in chronic HCV infection. Hepatology 41:5 (2005), 1019–1028.
121. [121] Ciurea, A., et al. Impairment of CD4+ T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 193:3 (2001), 297–306.
122. [122] Chen, C.H., et al. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 44:5 (2006), 1171–1181.
123. [123] Sakane, T., et al. Behçet's disease. N. Engl. J. Med. 341:17 (1999), 1284–1291.
124. [124] Sim, J., et al. Altered expression of costimulatory molecules in Behçet's disease according to clinical activity. Br. J. Dermatol. 164:6 (2011), 1285–1291.
125. [125] Conti-Fine, B.M., Milani, M., Kaminski, H.J., Myasthenia gravis: past, present, and future. J. Clin. Investig., 116(11), 2006, 2843.
126. [126] Nishimura, H., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:5502 (2001), 319–322.
127. [127] Sakthivel, P., et al. Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. J. Neuroimmunol. 193:1 (2008), 149–155.
128. [128] Selmi, C., Diagnosis and classification of autoimmune uveitis. Autoimmun. Rev. 13:4 (2014), 591–594.
129. [129] Meng, Q., et al. CD4+ PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest. Ophthalmol. Vis. Sci. 47:10 (2006), 4444–4452.
130. [130] Ashki, N., et al. Paradoxically decreased uveitis susceptibility in PD-L1/L2 double knockout mice. Invest. Ophthalmol. Vis. Sci., 56(7), 2015, 850.
131. [131] Sugita, S., et al. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. Invest. Ophthalmol. Vis. Sci. 50:1 (2009), 263–272.
132. [132] Manoussakis, M.N., Moutsopoulos, H.M., Sjögren's syndrome: current concepts. Adv. Intern. Med., 47, 2001, 191.
133. [133] Moutsopoulos, H., Sjöc; gren's Syndrome: Autoimmune Epithelitis. Clin. Immunol. Immunopathol. 72:2 (1994), 162–165.
134. [134] Fox, R.I., et al. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J. Immunol. 152:11 (1994), 5532–5539.
135. [135] Ludewig, B., et al. Dendritic cells in autoimmune diseases. Curr. Opin. Immunol. 13:6 (2001), 657–662.
136. [136] Kobayashi, M., et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. J. Rheumatol. 32:11 (2005), 2156–2163.
137. [137] Zhang, X., et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20:3 (2004), 337–347.
138. [138] Nishimura, H., et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10:10 (1998), 1563–1572.
139. [139] Bertsias, G.K., et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 60:1 (2009), 207–218.
140. [140] Her, M., et al. Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus 18:6 (2009), 501–507.
141. [141] Mozaffarian, N., Wiedeman, A., Stevens, A., Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatology 47:9 (2008), 1335–1341.
142. [142] Liu, M.-F., Weng, C.-T., Weng, M.-Y., Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus. BioMed. Res. Int., 2009, 2009.
143. [143] Simpson, N., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62:1 (2010), 234–244.
144. [144] Kristjansdottir, H., et al. Lower expression levels of the programmed death 1 receptor on CD4+ CD25+ T cells and correlation with the PD-1.3 A genotype in patients with systemic lupus erythematosus. Arthritis Rheum. 62:6 (2010), 1702–1711.
145. [145] Okazaki, T., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9:12 (2003), 1477–1483.
146. [146] Wang, J., et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol., 2010, dxq026.
147. [147] Lucas, J.A., et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181:4 (2008), 2513–2521.
148. [148] Tarrio, M.L., et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol. 188:10 (2012), 4876–4884.
149. [149] Fiorillo, M.T., et al. CD8+ T-cell autoreactivity to an HLA-B27–restricted self-epitope correlates with ankylosing spondylitis. J. Clin. Investig., 106(1), 2000, 47.
150. [150] Szalay, B., et al. Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy. Clin. Dev. Immunol., 2012, 2011.
151. [151] Bautista-Caro, M.-B., et al. Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients naïve for TNF blockers. PLoS One, 9(9), 2014, e107086.
152. [152] Xiao, F., et al. Higher frequency of peripheral blood interleukin 21 positive follicular helper T cells in patients with ankylosing spondylitis. J. Rheumatol. 40:12 (2013), 2029–2037.
153. [153] Chen, M.-H., et al. Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis. Clin. Rheumatol. 30:9 (2011), 1181–1187.
154. [154] Bolland, S., Ravetch, J.V., Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13:2 (2000), 277–285.
155. [155] Carter, L.L., et al. PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur. J. Immunol. 32:3 (2002), 634–643.
156. [156] Yao, S., Chen, L., PD-1 as an Immune Modulatory Receptor. Cancer J. 20:4 (2014), 262–264.
157. [157] Lee, Y., et al. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 18:1 (2009), 9–15.
158. [158] Prokunina, L., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32:4 (2002), 666–669.
159. [159] Kong, E.K.P., et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 52:4 (2005), 1058–1062.
160. [160] Kroner, A., et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 58:1 (2005), 50–57.
161. [161] Lin, S.C., et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 50:3 (2004), 770–775.
162. [162] Lee, S., et al. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res. Ther., 8(6), 2006, R163.
163. [163] Liu, X., et al. Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatol. Int. 31:2 (2011), 209–213.
164. [164] Nielsen, C., et al. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62:6 (2003), 492–497.
165. [165] Alarcón-Riquelme, M.E., Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus. Arthritis Res. Ther., 6, 2004, 169.
166. [166] Fawwaz, S., et al. No evidence of association of the PDCD1 gene with Type 1 diabetes. Diabet. Med. 24:12 (2007), 1473–1477.
167. [167] Ferreiros-Vidal, I., et al. Association of PDCD1 with susceptibility to systemic lupus erythematosus. Arthritis Rheum. 50:8 (2004), 2590–2597.
168. [168] Mahmoudi, M., et al. PDCD1 single nucleotide genes polymorphisms confer susceptibility to juvenile-onset systemic lupus erythematosus. Autoimmunity, 2015, 1–6.
169. [169] Prokunina, L., et al. Association of the PD-1.3 A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum. 50:6 (2004), 1770–1773.
170. [170] Iwamoto, T., et al. Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. J. Hum. Genet. 52:6 (2007), 557–560.
171. [171] Tahoori, M., et al. Association of programmed cell death-1 (PDCD-1) gene polymorphisms with rheumatoid arthritis in Iranian patients. Clin. Exp. Rheumatol. 29:5 (2010), 763–767.
172. [172] Pedersen, O., et al. Ankylosing spondylitis in Danish and Norwegian twins: occurrence and the relative importance of genetic vs. environmental effectors in disease causation. Scand. J. Rheumatol. 37:2 (2008), 120–126.
173. [173] Yang, Q., et al. Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population. Clin. Exp. Rheumatol. 29:1 (2010), 13–18.
174. [174] Soleimanifar, N., et al. Study of programmed cell death 1 (PDCD1) gene polymorphims in Iranian patients with ankylosing spondylitis. Inflammation 34:6 (2011), 707–712.
175. [175] Yang, M., et al. The programmed cell death 1 gene polymorphisms (PD 1.3 G/A, PD 1.5 C/T and PD 1.9 C/T) and susceptibility to ankylosing spondylitis: a meta-analysis. J. Orthop. Sci. 20:1 (2014), 55–63.
176. [176] Zamani, M.R., et al. Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men. J. Assist. Reprod. Genet. 32:1 (2015), 103–106.
177. [177] James, E., et al. PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun. 6:5 (2005), 430–437.
178. [178] El-Roeiy, A., et al. Autoantibodies and common idiotypes in men and women with sperm antibodies. Am. J. Obstet. Gynecol. 158:3 (1988), 596–603.
179. [179] Hirata, S., et al. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J. Immunol. 174:4 (2005), 1888–1897.
180. [180] Senju, S., et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood 101:9 (2003), 3501–3508.
181. [181] Ding, H., et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin. Immunol. 118:2 (2006), 258–267.
182. [182] Hughes, T., et al. Evidence for gene–gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum. 64:2 (2012), 485–492.
183. [183] Wang, S.-C., et al. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J. Clin. Immunol. 26:6 (2006), 506–511.
184. [184] Thorburn, C., et al. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun. 8:4 (2007), 279–287.
185. [185] Liu, J.L., et al. Association between the PD1. 3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J. Eur. Acad. Dermatol. Venereol. 23:4 (2009), 425–432.
186. [186] Abelson, A.-K., et al. No evidence of association between genetic variants of the PDCD1 ligands and SLE. Genes Immun. 8:1 (2007), 69–74.
187. [187] Flores, S., et al. Programmed cell death 1 (PDCD1) gene polymorphisms and type 1 diabetes in Chilean children. Rev. Med. Chil. 138:5 (2010), 543–550.
188. [188] Fichna, M., et al. PTPN22, PDCD1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Polish patients. Int. J. Immunogenet. 37:5 (2010), 367–372.
189. [189] Ni, R., et al. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum. Genet. 121:2 (2007), 223–232.
190. [190] Momin, S., et al. Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Res. Clin. Pract. 83:3 (2009), 289–294.
191. [191] Cooper, J.D., et al. The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med. Genet., 8(1), 2007, 71.